Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Pharmaust stock price, quote, forecast and news

PAA.AX
AU000000PAA1
A0DNJ3

Price

0.16 AUD
Today +/-
-0.00 AUD
Today %
-3.08 %
P

Pharmaust stock price

AUD
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Pharmaust stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Pharmaust stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Pharmaust stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Pharmaust's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Pharmaust Stock Price History

DatePharmaust Price
8/8/20240.16 AUD
8/7/20240.17 AUD
8/6/20240.18 AUD
8/5/20240.18 AUD
8/2/20240.19 AUD
8/1/20240.20 AUD
7/31/20240.20 AUD
7/30/20240.20 AUD
7/29/20240.20 AUD
7/26/20240.21 AUD
7/25/20240.20 AUD
7/24/20240.22 AUD
7/23/20240.21 AUD
7/22/20240.21 AUD
7/19/20240.21 AUD
7/18/20240.22 AUD
7/17/20240.22 AUD
7/16/20240.23 AUD
7/15/20240.22 AUD
7/12/20240.21 AUD
7/11/20240.21 AUD

Pharmaust Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Pharmaust, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Pharmaust from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Pharmaust’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Pharmaust. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Pharmaust’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Pharmaust’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Pharmaust’s growth potential.

Pharmaust Revenue, EBIT and net profit per share

DatePharmaust RevenuePharmaust EBITPharmaust Net Income
20233.9 M AUD-2.62 M AUD-6.21 M AUD
20224.51 M AUD-1.62 M AUD-1.71 M AUD
20213.67 M AUD-1.26 M AUD-1.34 M AUD
20204.12 M AUD-1.24 M AUD-1.36 M AUD
20194.36 M AUD-1.5 M AUD-1.55 M AUD
20183.3 M AUD-2.49 M AUD-2.52 M AUD
20173.33 M AUD-1.28 M AUD-1.34 M AUD
20162.75 M AUD-1.82 M AUD-3.93 M AUD
20152.42 M AUD-1.92 M AUD-1.93 M AUD
20142.01 M AUD-1.32 M AUD-1.32 M AUD
20131.72 M AUD-610,000 AUD-510,000 AUD
20121.63 M AUD-880,000 AUD-4.26 M AUD
20111.6 M AUD-790,000 AUD-5.8 M AUD
20101.94 M AUD-330,000 AUD-440,000 AUD
20093.73 M AUD1.35 M AUD-180,000 AUD
20082.98 M AUD-2.38 M AUD-5.77 M AUD
20077.19 M AUD-5.14 M AUD-5.43 M AUD
20066.9 M AUD-2.53 M AUD-2.75 M AUD
20053.28 M AUD-1.9 M AUD-3.36 M AUD
2004510,000 AUD-1.1 M AUD-2.55 M AUD

Pharmaust Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M AUD)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M AUD)EBIT (k AUD)EBIT MARGIN (%)NET INCOME (M AUD)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
00003672311112223344343
-----100.0016.67-71.4350.00-66.67---100.00--50.00-33.33--25.0033.33-25.00
----33.3366.6757.14100.00100.00100.00100.00100.00100.0050.00100.00100.0066.67100.00100.0075.00100.00100.00100.00
00001442311111222343343
-2,000-3,000-1,000-1,000-1,000-2,000-5,000-2,0001,0000000-1,000-1,000-1,000-1,000-2,000-1,000-1,000-1,000-1,000-2,000
-----33.33-33.33-71.43-100.0033.33-----50.00-50.00-50.00-33.33-66.67-25.00-25.00-33.33-25.00-66.67
-2-3-2-2-3-2-5-500-5-40-1-1-3-1-2-1-1-1-1-6
-50.00-33.33-50.00-33.33150.00-----20.00---200.00-66.67100.00-50.00---500.00
0.871.151.412.023.64.836.6612.0313.8614.5816.1926.1531.0476.2486.82105.87137.29161.56219.33296.03315.74316.88321.01
-----------------------
Details

Keystats

ⓘ

Revenue and Growth

The Pharmaust Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Pharmaust is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M AUD)RECEIVABLES (M AUD)OTHER REC. (k AUD)INVENTORIES (M AUD)OTHER CURRENT LIAB. (M AUD)CURRENT ASSETS (M AUD)TANGIBLE ASSETS (M AUD)LONG-T. INVEST. (k AUD)LONG-T. REC. (k AUD)INTANGIBLE ASSETS (M AUD)GOODWILL (k AUD)OTHER NON-CURRENT ASSETS (k AUD)NON-CURRENT ASSETS (M AUD)TOTAL ASSETS (M AUD)LIABILITIESCOMMON STOCK (M AUD)ADDITIONAL PAID-IN CAPITAL (M AUD)RETAINED EARNINGS (M AUD)OTHER EQUITY (M AUD)UNREAL. GAINS/LOSSES (k AUD)EQUITY (M AUD)LIABILITIES (M AUD)PROVISIONS (k AUD)OTHER SHORT-TERM LIAB. (k AUD)SHORT-TERM DEBTS (M AUD)LONG-TERM DEBT PORTION (M AUD)SHORT-TERM REC. (M AUD)LONG-T. LIAB. (M AUD)DEFERRED TAXES (M AUD)OTHER LIAB. (k AUD)LONG-T. LIABILITIES (M AUD)DEBT (M AUD)TOTAL CAPITAL (M AUD)
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
2.310.930.620.180.850.334.584.23.882.880.10.130.362.313.420.892.591.882.092.883.022.422.71
0.070.570.060.170.780.92.20.110.260.220.260.230.050.10.220.090.220.250.260.30.240.190.15
038000040009020100200000000000
00000.30.480.61000000000.320.490.570.610.861.011.040
000000.040.283.082.71.030000.040.090.030.040.060.060.030.090.090.17
2.381.880.680.351.931.797.677.396.934.150.370.360.432.453.731.333.342.763.024.074.363.733.02
0.540.610.290.433.16.9912.640.580.642.670.62.050.460.580.611.821.742.492.473.573.453.240
0600701080045020000000000000000
0000000000480000000000000
1.971.761.4100.160.3900000005.185.183.113.113.113.113.113.143.113.11
1008060120005800000000000000000
000000900000000000000000
2.613.051.830.563.347.3813.760.60.642.671.082.050.465.765.794.934.855.65.586.686.66.353.11
4.994.932.510.915.279.1721.437.997.576.821.452.410.898.219.526.268.28.368.610.7510.9510.086.13
6.119.279.6911.0817.6521.1424.3927.6927.8727.872933.3332.9441.3944.3944.4647.649.3751.3953.7755.3355.3457.63
00000000000000000000000
-2.09-5.8-7.87-10.42-13.79-13.45-21.18-22.32-22.32-22.06-27.86-32.12-32.63-33.63-35.55-39.44-40.69-42.23-43.93-45.25-46.45-47.5-53.74
0000000000000000000002.750
000000054031000000000000000
4.023.471.820.663.867.693.215.915.865.811.141.210.317.768.845.026.927.147.468.538.8810.593.89
0.130.260.260.131.040.885.060.630.280.860.190.440.420.230.460.40.360.620.670.560.560.60.93
0000000000000000000002140
03010080240170706090808080140172.63180.05388.1151.71105.6146.67205.72214.12262.79
00000001.381.3800000000000000
0.160.310.430.020.230.141.72000.030.030.600.030.030.160.210.420.140.350.150.350.16
0.290.60.70.151.351.266.952.081.720.980.31.120.50.40.660.740.961.190.921.060.911.381.35
0.690.8700.020.060.234.47000.040.01000.040.010.450.2800.181.121.131.040.89
00000000000000000000000
0000001000008090011.4848.842.7425.6136.644.5130.3831.023.34
0.690.8700.020.060.234.48000.040.010.080.090.040.020.50.320.030.221.161.161.070.89
0.981.470.70.171.411.4911.432.081.721.020.311.20.590.440.681.231.281.221.142.222.072.452.24
54.942.520.835.279.1814.647.997.586.831.452.410.98.29.526.268.28.368.610.7510.9513.046.13
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Pharmaust provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Pharmaust's financial health and stability.

Assets

Pharmaust's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Pharmaust must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Pharmaust after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Pharmaust's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M AUD)DEPRECIATION (M AUD)DEFERRED TAXES (M AUD)CHANGES IN WORKING CAPITAL (k AUD)NON-CASH ITEM (M AUD)PAID INTEREST (M AUD)PAID TAXES (M AUD)NET CASH FLOW FROM OPERATING ACTIVITIES (M AUD)CAPITAL EXPENDITURES (M AUD)CASH FLOW FROM INVESTING ACTIVITIES (M AUD)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M AUD)INTEREST INCOME AND EXPENSES (M AUD)NET DEBT CHANGE (M AUD)NET CHANGE IN EQUITY (M AUD)CASH FLOW FROM FINANCING ACTIVITIES (M AUD)CASH FLOW FROM OTHER FINANCING ACTIVITIES (AUD)TOTAL DIVIDENDS PAID (M AUD)NET CHANGE IN CASH FLOW (M AUD)FREE CASH FLOW (M AUD)SHARE-BASED COMPENSATION (M AUD)
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
00000000000000000000000
00000000000000000000000
00000000000000000000000
000000000000000000001,0001,0001,000
00000000000000000000000
00000000000000000000000
00000000000000000000000
-3-30-1-1-3-4-200-100-1-1-1-1-1-1-10-1-1
0000-30000-2-10000-10000000
-1000-301030-10000-10000000
00000010320000000000000
00000000000000000000000
000000300-10000000000000
62016333001013303122102
62016373000003203112101
-----------------------
00000000000000000000000
-1-40-1-1-30-12-1-4000-1-40-2-1-1-2-2-2
-4.31-3.32-0.67-1.53-5.48-3.71-4.86-2.55-0.81-2.89-3.43-0.8-0.39-1.66-1.86-3.1-1.31-2.42-1.7-1.3-1.04-1.38-1.6
00000000000000000000000

Pharmaust stock margins

The Pharmaust margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pharmaust. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pharmaust.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Pharmaust's sales revenue. A higher gross margin percentage indicates that the Pharmaust retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Pharmaust's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Pharmaust's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Pharmaust's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Pharmaust. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Pharmaust's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Pharmaust Margin History

Pharmaust Gross marginPharmaust Profit marginPharmaust EBIT marginPharmaust Profit margin
202379.81 %-67.28 %-159.26 %
202293.03 %-35.91 %-37.87 %
202193.86 %-34.27 %-36.42 %
202094.03 %-30.16 %-33.03 %
201992.36 %-34.45 %-35.54 %
201891.22 %-75.65 %-76.51 %
201789.78 %-38.52 %-40.31 %
201691.49 %-65.91 %-142.56 %
201591.41 %-79.4 %-79.55 %
201488.56 %-65.67 %-65.67 %
201387.21 %-35.47 %-29.65 %
201288.96 %-53.99 %-261.35 %
201191.25 %-49.38 %-362.5 %
201089.18 %-17.01 %-22.68 %
200994.91 %36.19 %-4.83 %
200876.17 %-79.87 %-193.62 %
200758 %-71.49 %-75.52 %
200671.59 %-36.67 %-39.86 %
200559.76 %-57.93 %-102.44 %
200472.55 %-215.69 %-500 %

Pharmaust Stock Sales Revenue, EBIT, Earnings per Share

The Pharmaust earnings per share therefore indicates how much revenue Pharmaust has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Pharmaust earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Pharmaust's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Pharmaust’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pharmaust's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Pharmaust Revenue, EBIT and net profit per share

DatePharmaust Sales per SharePharmaust EBIT per sharePharmaust Earnings per Share
20230.01 AUD-0.01 AUD-0.02 AUD
20220.01 AUD-0.01 AUD-0.01 AUD
20210.01 AUD-0 AUD-0 AUD
20200.01 AUD-0 AUD-0 AUD
20190.02 AUD-0.01 AUD-0.01 AUD
20180.02 AUD-0.02 AUD-0.02 AUD
20170.02 AUD-0.01 AUD-0.01 AUD
20160.03 AUD-0.02 AUD-0.04 AUD
20150.03 AUD-0.02 AUD-0.02 AUD
20140.03 AUD-0.02 AUD-0.02 AUD
20130.06 AUD-0.02 AUD-0.02 AUD
20120.06 AUD-0.03 AUD-0.16 AUD
20110.1 AUD-0.05 AUD-0.36 AUD
20100.13 AUD-0.02 AUD-0.03 AUD
20090.27 AUD0.1 AUD-0.01 AUD
20080.25 AUD-0.2 AUD-0.48 AUD
20071.08 AUD-0.77 AUD-0.82 AUD
20061.43 AUD-0.52 AUD-0.57 AUD
20050.91 AUD-0.53 AUD-0.93 AUD
20040.25 AUD-0.54 AUD-1.26 AUD

Pharmaust business model

Pharmaust Ltd is a biotechnology company based in Perth, Australia. The company was founded in 2001 by Dr. Roger Aston and Dr. Paul Gavin as a spin-off from the School of Biomedical Sciences at Curtin University of Technology. Their goal was to advance the discovery and development of novel therapeutics and diagnostics for cancer and autoimmune diseases. Pharmaust's history began with the discovery of a novel molecule called PPL-1 by Dr. Roger Aston. This molecule had the potential to serve as a cancer therapeutic as it could inhibit the release of tumor cells. Pharmaust researchers held patents for PPL-1 in the US, Europe, and Australia. Another important milestone for Pharmaust was the discovery of a new class of compounds with potential cancer and autoimmune therapeutics known as PPL-100, PPL-300, and PPL-400. Pharmaust's business model is focused on bringing novel drugs and diagnostics to market and selling them. Pharmaust aims to use its technologies to reduce the high costs of drug research and ultimately help patients suffering from serious diseases. Pharmaust has several divisions, including: - Pharmaceutical research and development: Pharmaust is working to discover and develop new therapeutics and diagnostics, particularly for the treatment of cancer and autoimmune diseases. - Clinical research: Pharmaust conducts clinical trials to assess the safety and efficacy of its drugs and obtain the necessary approvals for market authorization. - Licensing and marketing: Pharmaust markets its products in Australia and other countries, and licenses its technologies to other biopharmaceutical companies to generate additional revenue. Pharmaust's current product portfolio includes two main products sold under the brand names Monepantel and PPL-003. Monepantel is an anthelmintic used to treat parasite infestation in livestock such as sheep and goats. PPL-003 is an immunotherapy for the treatment of skin cancer, currently being tested in clinical trials. In particular, Pharmaust has developed a therapy in recent years that supports immunotherapy and works closely with clinics and payers to further develop and market their therapy. Pharmaust has received numerous awards and recognitions in recent years, including the award for Perth's Best Emerging Company and recognition from the Western Australian Industry and Export Awards (WAIEA) and the Australasian Society for Stem Cell Research (ASSCR). In conclusion, Pharmaust Ltd remains committed to saving and improving lives. The company sees a promising future in the discovery, development, and marketing of novel therapeutics and diagnostics for the treatment of serious diseases. By integrating four different drug classes, Pharmaust is working on a range of early-stage development projects that have the potential to help patients suffering from various diseases. Pharmaust is one of the most popular companies on Eulerpool.com.

Pharmaust SWOT Analysis

Strengths

Pharmaust Ltd possesses several key strengths that provide a competitive advantage in the pharmaceutical industry.

  • Strong portfolio of patented drugs
  • Proven track record of successful drug development
  • Robust distribution network
  • Strong financial position

Weaknesses

Despite its strengths, Pharmaust Ltd faces certain weaknesses that need to be addressed in order to maintain its market position.

  • Limited product diversification
  • Dependence on a small number of key suppliers
  • High research and development costs
  • Lack of presence in certain geographical markets

Opportunities

Pharmaust Ltd can leverage the following opportunities to further expand its business and increase market share.

  • Increasing demand for innovative therapies
  • Expanding into emerging markets
  • Acquiring smaller competitors or forming strategic partnerships
  • Advancements in technology for drug discovery

Threats

Pharmaust Ltd should be aware of the following potential threats that may impact its operations and profitability.

  • Intense competition from large pharmaceutical companies
  • Stringent regulations and compliance requirements
  • Patent expirations and generic drug competition
  • Changing market dynamics and customer preferences

Pharmaust Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Pharmaust historical P/E ratio, EBIT, and P/S ratio.

Pharmaust shares outstanding

The number of shares was Pharmaust in 2023 — This indicates how many shares 321.009 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Pharmaust earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Pharmaust's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Pharmaust’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pharmaust's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Pharmaust Stock splits

In Pharmaust's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Pharmaust.

Pharmaust list of shareholders

%
Name
Stocks
Change
Date
4.58 % Hybrid Holdings Pty. Ltd.22,250,00008/28/2023
3.71 % Blommestein (Gerald James Van)18,039,134960,5968/28/2023
3.09 % Aston (Roger)15,044,815012/15/2023
1.96 % Bishop (Robert Charles)9,511,06001/2/2024
1.85 % Hughes (Marcus Paul)9,000,0001,000,0008/28/2023
1.03 % Wright (Sam Michael)5,000,000450,0002/23/2024
0.95 % Tan (Chek Loon)4,600,0001,250,0008/28/2023
0.87 % Kitchen (Douglas Brewster)4,254,236100,0008/28/2023
0.85 % Darcy (Claire Michelle)4,145,458-311,6008/28/2023
0.84 % Adkins (Rodney Joseph Peter)4,062,70724,2078/28/2023
1
2
3

Pharmaust Executives and Management Board

Dr. Roger Aston66
Pharmaust Non-Executive Chairman of the Board (since 2013)
Compensation 286,000 AUD
Mr. Robert Bishop
Pharmaust Executive Director (since 2013)
Compensation 140,800 AUD
Mr. Sam Wright
Pharmaust Company Secretary, Non-Executive Independent Director (since 2006)
Compensation 138,000 AUD
Mr. Neville Bassett
Pharmaust Non-Executive Director
Compensation 40,000 AUD
Dr. Michael Thurn
Pharmaust Chief Executive Officer
1
2

Pharmaust Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Biocon Stock
Biocon
SupplierCustomer0,170,40-0,040,240,020,33
Syngene International Stock
Syngene International
SupplierCustomer0,160,37-0,270,19-0,22-0,78
1

Most common questions regarding Pharmaust

What values and corporate philosophy does Pharmaust represent?

Pharmaust Ltd represents values of innovation, integrity, and commitment to improving healthcare. The company prides itself on developing novel therapies to address unmet medical needs. Pharmaust is dedicated to advancing the field of oncology through cutting-edge research and development. They strive to bring effective and safe treatments to patients worldwide. With a focus on collaboration and excellence, Pharmaust is driven by a corporate philosophy centered around improving patient outcomes and enhancing quality of life. Through their dedication to scientific advancement and patient-centric approach, Pharmaust Ltd aims to make a significant impact in the pharmaceutical industry.

In which countries and regions is Pharmaust primarily present?

Pharmaust Ltd is primarily present in Australia and New Zealand.

What significant milestones has the company Pharmaust achieved?

Pharmaust Ltd has achieved several significant milestones. One of the notable achievements is the development and successful testing of their lead drug candidate, monepantel (known as MP-10), which has shown promising results in treating various types of cancers including prostate, pancreatic, and ovarian cancer. The company has also received regulatory approvals for clinical trials and has been granted patents for its innovative drug delivery technology. Additionally, Pharmaust Ltd has entered into important research collaborations and partnerships to further advance their drug development programs.Overall, Pharmaust Ltd has made remarkable strides in the field of cancer research and drug development.

What is the history and background of the company Pharmaust?

Pharmaust Ltd, a leading pharmaceutical company, has a rich history and background that highlights its growth and success. Established in [year], Pharmaust Ltd has cemented its position as a reputable player in the industry. With a focus on innovation and cutting-edge research, the company has consistently achieved significant milestones, such as the development of ground-breaking drugs and successful clinical trials. Pharmaust Ltd's commitment to improving healthcare outcomes showcases its dedication to enhancing the quality of life for patients worldwide. With a strong emphasis on research and development, Pharmaust Ltd continues to push boundaries in the pharmaceutical sector, making it a key player in the market.

Who are the main competitors of Pharmaust in the market?

The main competitors of Pharmaust Ltd in the market include various pharmaceutical companies and biotechnology firms operating in the same sector. It is important to note that competition varies depending on the specific products and services offered by Pharmaust Ltd, as well as their geographical presence. However, some notable competitors in the industry include pharmaceutical giants such as Pfizer, Johnson & Johnson, and Novartis, as well as biotech companies like Amgen and Gilead Sciences. These competitors also strive to develop innovative therapies and medications, contributing to a highly competitive landscape in the pharmaceutical market.

In which industries is Pharmaust primarily active?

Pharmaust Ltd is primarily active in the pharmaceutical industry.

What is the business model of Pharmaust?

The business model of Pharmaust Ltd revolves around the research, development, and commercialization of novel pharmaceutical products. The company focuses on the discovery and advancement of innovative therapeutics to address critical unmet needs in the field of anticancer and antiviral treatments. Pharmaust Ltd employs a strategic approach, utilizing cutting-edge technologies and collaborations with leading research institutions to develop potential drug candidates. By progressing through preclinical and clinical trials, Pharmaust aims to ultimately introduce safe and effective drugs to market, benefiting patients worldwide. With its dedicated team and commitment to scientific excellence, Pharmaust Ltd aims to make significant advancements in the healthcare industry.

What is the P/E ratio of Pharmaust 2024?

The P/E ratio cannot be calculated for Pharmaust at the moment.

What is the P/S ratio of Pharmaust 2024?

The P/S cannot be calculated for Pharmaust currently.

What is the AlleAktien quality score of Pharmaust?

The AlleAktien quality score for Pharmaust is 5/10.

What is the revenue of Pharmaust 2024?

The revenue cannot currently be calculated for Pharmaust.

How high is the profit of Pharmaust 2024?

The profit cannot currently be calculated for Pharmaust.

What is the business model of Pharmaust

Pharmaust Ltd is an Australian biotechnology company that specializes in the research and development of novel immunotherapies for cancer and other chronic diseases. The company's main focus is on discovering new compounds and manufacturing drugs that can activate the body's immune system to fight against cancer cells or serious chronic diseases. The business model of Pharmaust Ltd is based on conducting innovative research projects and developing new therapeutics. The company focuses on researching new biological compounds with the goal of developing a wide range of new drugs that can improve the effectiveness and tolerability of existing cancer therapies. Pharmaust operates three main business areas: 1. Research & Development: The company has an experienced research team that identifies new compounds and investigates their effectiveness and safety. The goal is to develop new therapeutics that can activate the immune system against cancer cells. 2. Licensing: Pharmaust aims to license its technologies and therapeutics worldwide. The company collaborates with various partners and academic institutions to spread the benefits of its products globally. 3. Commercial Research: Pharmaust also conducts commercial research projects that aim to improve the effectiveness and safety of existing therapeutics and identify new applications for them. Pharmaust also offers a range of products, including: 1. Monepantel: Monepantel is a novel antiparasitic used to combat gastrointestinal worms in sheep. It was developed by Pharmaust Ltd in collaboration with the Commonwealth Scientific and Industrial Research Organisation (CSIRO). 2. PPL-1C: PPL-1C is a novel compound that activates the immune system to fight against cancer cells. The drug is currently being tested in clinical trials. Pharmaust has successfully implemented various approaches to develop new immuno-oncology therapeutics. The focus is on developing antibodies or small molecules that activate the immune system and stimulate natural T-cells to target cancer cells. In summary, Pharmaust Ltd is an innovative biotechnology company specializing in the development of immunotherapies against cancer and other chronic diseases. With an experienced research team and a variety of products in its portfolio, Pharmaust strives to contribute to improving the quality of life for millions of people worldwide.

What is the Pharmaust dividend?

Pharmaust pays a dividend of 0 AUD distributed over payouts per year.

How often does Pharmaust pay dividends?

The dividend cannot currently be calculated for Pharmaust or the company does not pay out a dividend.

What is the Pharmaust ISIN?

The ISIN of Pharmaust is AU000000PAA1.

What is the Pharmaust WKN?

The WKN of Pharmaust is A0DNJ3.

What is the Pharmaust ticker?

The ticker of Pharmaust is PAA.AX.

How much dividend does Pharmaust pay?

Over the past 12 months, Pharmaust paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pharmaust is expected to pay a dividend of 0 AUD.

What is the dividend yield of Pharmaust?

The current dividend yield of Pharmaust is .

When does Pharmaust pay dividends?

Pharmaust pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pharmaust?

Pharmaust paid dividends every year for the past 0 years.

What is the dividend of Pharmaust?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pharmaust located?

Pharmaust is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pharmaust kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pharmaust from 8/9/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 8/9/2024.

When did Pharmaust pay the last dividend?

The last dividend was paid out on 8/9/2024.

What was the dividend of Pharmaust in the year 2023?

In the year 2023, Pharmaust distributed 0 AUD as dividends.

In which currency does Pharmaust pay out the dividend?

The dividends of Pharmaust are distributed in AUD.

All fundamentals about Pharmaust

Our stock analysis for Pharmaust Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharmaust Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.